NCT07025746

Brief Summary

The purpose of this study is to verify the immediate effects of gastrocnemius myofascial release on the active cervical flexion and extension range of motion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 9, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

June 15, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 17, 2025

Completed
17 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 4, 2025

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2025

Completed
Last Updated

May 6, 2026

Status Verified

May 1, 2026

Enrollment Period

19 days

First QC Date

June 9, 2025

Last Update Submit

May 5, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of active cervical range of motion in flexion and extension.

    Data will be collected at two time points: baseline assessment (M0) and after the intervention/control (M1). Participants will be instructed to sit with their spine straight and supported against the backrest of the chair, with ankles, knees, and hips positioned at 90 degrees. Arms will remain crossed over the chest to prevent compensatory thoracic movements. Before the test begins, each participant will be asked to actively perform the flexion and extension movements to the limit of their range of motion, aiming to reduce stiffness and promote familiarization with the assessment protocol. Measurements will be taken three times for each movement (active flexion and extension), with 30-second rest intervals between each measurement. The average of the three values will be calculated and recorded as the final value.

    Change from Baseline (M0) to Immediately after intervention or control (M1)

Study Arms (2)

Intervention group

ACTIVE COMPARATOR

A myofascial release technique will be performed using a foam roller (Blackroll Standard, 30 x 15 cm) on the dominant lower limb. For the Intervention Group (IG), the technique will be applied to the gastrocnemius muscles. In this group, participants will adopt a semi-seated position on a mat, supported by their arms while keeping the body well aligned. The movement will be performed in the direction of the muscle fibers (cephalocaudal), ensuring the accuracy of the technique. The foam roller will be in contact with the targeted muscle, and the participant will apply pressure until experiencing slight discomfort. In this way, a self-massage will be performed following the direction of the muscle fibers.

Device: Dynamic foam rolling

Control group

NO INTERVENTION

The participants will remain at rest in a chair for 4 minutes.

Interventions

The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.

Intervention group

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy participants of both sexes aged 18-40 years.

You may not qualify if:

  • Deformities in the lower quadrant region of the body;
  • Complaints in this region in the last 6 months;
  • Surgical procedures or musculoskeletal, cardiac, renal, metabolic, neurological and or oncological pathologies;
  • Limb length discrepancy greater than 1.5 cm;
  • Pregnant women;
  • Ingestion of non-steroidal anti-inflammatory drugs or consumption of any type of narcotic drugs and participants who have drunk alcohol in the last 12 hours.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Escola Superior de Saúde Fernando Pessoa

Porto, 4249-004, Portugal

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Phd

Study Record Dates

First Submitted

June 9, 2025

First Posted

June 17, 2025

Study Start

June 15, 2025

Primary Completion

July 4, 2025

Study Completion

July 30, 2025

Last Updated

May 6, 2026

Record last verified: 2026-05

Locations